Apira Science, Inc. Announces Successful Completion of Clinical Trial for the Treatment of Androgenetic Alopecia in Males

IRVINE, CA--(Marketwire - July 25, 2012) -

Highlighted Links

Apira Science - Outside US

Apira Science, Inc. today announced that it has successfully completed a clinical trial using its visible red light laser/LED system for promoting hair growth in males. This randomized, double blind, placebo controlled prospective study was conducted at multiple sites in the U.S. The principal investigator was Raymond Lanzafame, MD MBA FACS. The trial was designed to evaluate the efficacy of low level light therapy (LLLT) for promoting hair growth in males diagnosed with androgenetic alopecia of the head.

The clinical trial involved 22 male subjects at two separate sites (44 total subjects) with skin phototypes classified as I-IV on the Fitzpatrick scale with hair loss patterns of IIa-V on the Hamilton-Norwood scale. Subjects were randomly assigned to either the active laser/LED group or the placebo group. All subjects were given a wearable system to take home and use 4 times per week for 25 minutes per session in accordance with the Institutional Review Board (IRB) approved protocol. The primary goal was to demonstrate the percent increase in terminal hair counts from baseline at the end of 16 weeks of treatment.

Commenting on the results of this trial, the principal investigator, Dr. Raymond Lanzafame said, "Research on the use of low level light therapy to treat male pattern baldness is ongoing. In this IRB approved study in male patients with androgenetic alopecia, the preliminary results of low level light therapy demonstrate this treatment strategy is efficacious. It is anticipated that laser and light based technologies will play an important role in managing this condition in the future."

"We are very pleased with the results of this study which clearly demonstrate the effectiveness of our innovative system," commented Jeff Braile, director of research at Apira Science, Inc. "This study validates LLLT as a viable treatment option for healthy men with androgenetic alopecia."

About Androgenetic Alopecia
Androgenetic alopecia is a common form of hair loss in both men and women. This condition occurs more frequently in men and affects approximately 35 million males in the United States. The onset of androgenetic alopecia can occur as early as the teen years and progress throughout life. It is estimated that majority of men over the age of 50 have some degree of hair loss.

About Apira Science, Inc.
Apira Science, Inc. is an established leader and has been a pioneer in low level light therapy (LLLT) for over a decade. Their latest product is the result of Apira Science, Inc.'s experience, scientific innovation and knowledge of the application of LLLT. This patented home use device is hands free, easy to use and offers full scalp coverage.